摘要
2013年6月,美国医学会首次宣称肥胖是一种疾病。早在19世纪末西方就已出现用药物来治疗肥胖的方法。许多曾被广泛应用的减肥药物因安全性问题被撤市。随着超重和肥胖的人数逐渐增多,人们对肥胖症及相关疾病的危害越来越重视,不断有新的减肥药物上市。2012年至今,美国食品药品监督管理局陆续批准了氯卡色林、芬特明托吡酯缓释胶囊、安非他酮纳曲酮缓释片以及利拉鲁肽注射剂用于肥胖症治疗。治疗药物的增加也推动了美国内分泌学会于2015年1月发布了第一部肥胖症的药物治疗临床指南。目前上市的减肥药物都存在不同的不良反应,在使用时应该谨慎选择。本文回顾了减肥药物的发展历史,阐述了现有减肥药物的作用机制、不良反应及注意事项,以期促进减肥药物合理使用,探讨未来减肥药物的发展方向。
The American Medical Association for first time in its history declared obesity as a chronic disease in 2013. Pharmacotherapy for obesity began to come out in the late 19 th century. Many widely used anti-obesity drugs were withdrawn for safety problems. With the rise of obesity epidemic all over the world,people pay more attention to obesity and its related diseases and new drugs appear on the market continuously. From 2012,FDA approved Lorcaserin,Controlled-release Phentermine / Topiramate,Controlled-release Phentermine / Topiramate and Liraglutide injection for obesity. The growth in the number of anti-obesity drugs promoted the Endocrine Society to publish the first guideline for pharmacological management of obesity in Jan 2015. This passage reviews the history,action mechanism and adverse reactions of anti-obesity drugs,in order to improve the rational use of anti-obsity drugs and discuss the developing direction of anti-obesity drugs.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第2期163-169,共7页
Chinese Journal of New Drugs
关键词
肥胖症
药物治疗
进展
不良反应
obesity
pharmacotherapy
development
adverse drug reactions
